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Abstract 
 
The thioredoxin system, comprising thioredoxin (Trx), thioredoxin reductase (TrxR) and NADPH, is one of the 
major cellular antioxidant systems, implicated in a large and growing number of biological functions. Trx acts 
as an oxidoreductase via a highly conserved dithiol/disulfide motif located in the active site (-Trp-Cys-Gly-Pro-
Cys-Lys-). Different factors are involved in the regulation of Trx activity, including its expression level, 
localization, protein-protein interactions, post-translational modifications and some chemical inhibitors. 
Mammalian TrxRs are selenoproteins which have a –Cys-Val-Asn-Val-Gly-Cys- N-terminal active site, as well 
as a C-terminal selenium-containing active site. Besides two Cys-residues in the redox-regulatory domain of 
cytosolic Trx (Trx1), human Trx1 has three additional Cys-residues. Post-translational modifications of human 
Trx1 which are involved in the regulation of its activity can happen via modification of Cys-residues including 
thiol oxidation, glutathionylation and S-nitrosylation or via modification of other amino acid residues such as 
nitration of Tyr-49. Because of the numerous functions of the thioredoxin system, its inhibition (mainly 
happens via the targeting TrxR) can result in major cellular consequences, which are potentially pro-oxidant in 
nature, leading to cell death via necrosis or apoptosis if overexpression of Trx and other antioxidative enzymes 
can not recuperate cell response. Considering this feature, several anticancer drugs have been used which can 
inhibit TrxR. Elevated levels of Trx and/or TrxR have been reported in many different human malignancies, 
positively correlated with aggressive tumor growth and poor prognosis. Moreover, anti-oxidative and anti-
apoptotic effects of Trx are reasons to study its clinical application as a drug. 
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Introduction 
The thioredoxin system, comprising 
thioredoxin (Trx), thioredoxin reductase (TrxR) 
and NADPH, is one of the major antioxidant 
systems applied by cells to provide and 
maintain reduced states in intracellular 
environment (1) as well as defending against 
oxidative and nitrosative stress (2, 3).  
The thioredoxin system is a major cellular 
protein disulfide reductase for which Trx 
provides electrons for protein disulfides 
reduction (1). After a non-covalent binding 
between a hydrophobic surface area around the 
active site of Trx and the target protein-
disulfide, the target disulfide undergoes a 
nucleophilic attack by the surface-exposed N-
terminal thiolate group of Trx’s active site. This 
reaction leads to the transient formation of a 
mixed disulfide intermediate which is 
subsequently reduced by the C-terminal thiolate 
group, causing the reduction of the target 
protein-disulfide accompanied by the oxidation 
of the active site in Trx (Reaction 1). 
Thereafter, oxidized Trx is reduced by NADPH 
via a reaction catalyzed with TrxR (Reaction 2) 
(4). This thiol-disulfide exchange reaction is 
reversible and efficient for electron transport. 
 
Trx-(SH)2  +  Protein-S2                     Trx-S2  +  
Protein-(SH)2          (1) 
Trx-S2  +  NADPH  +  H
+     TrxR        Trx-
(SH)2 + NADP
+      (2) 
 
In addition, the Trx system is implicated in a 
large and growing number of other biological 
functions such as DNA synthesis and cell 
proliferation (5, 6), angiogenesis (7), control 
and regulation of numerous transcription 
factors activities (8-9), protecting cells against 
apoptosis (10, 11), as well as involvement in 
cell signaling pathways through the interaction 
with other proteins (12, 13). 
Thioredoxin is a small protein, ubiquitously 
present in various species and tissues (14, 15); 
however, the active site is highly conserved         
(-Trp-Cys-Gly-Pro-Cys-Lys-) among species 
from bacteria to humans (16). In mammals, 
three different forms of Trx have been 
described which are Trx1, Trx2, and SpTrx. 
Trx1 is localized mainly in cytosol; however, it 
can be translocated to the nucleus with an 
unknown mechanism (17). This translocation 
has been reported to happen after treatment of 
cells with the cancer drug cisplatin (18), UV 
irradiation (19), H2O2 (20), and hypoxia (21). It 
is also detected in nucleus of normal cells (22) 
as well as tumors (23). Human Trx2 is a 
mitochondrial protein which has the conserved 
catalytic active site of Trx, but lacks the 
structural cysteine residues. SpTrxs are tissue-
specific members of this family which do not 
have thiol-disulfide oxidoreductase activity 
despite their Trx domain (24). 
Trx1 can be secreted from a variety of normal 
cells such as hepatocytes, fibroblasts, and 
activated monocytes and lymphocytes as well 
as transformed and cancer cells. For example, 
adult T cell leukemia-derived factor (ADF) 
which had been first identified as a growth 
factor secreted by human T lymphotropic virus 
I-transformed leukemic cell lines was later 
shown to be identical to human Trx (25). The 
precise mechanism of Trx1 secretion is 
unknown, but it mainly occurs under oxidizing 
conditions and inflammations (26). For 
example, elevated level of Trx in plasma has 
been reported during cardiovascular diseases 
such as heart failure and cardiomyopathy (27), 
abdominal aortic aneurysms (28), airway-
related disorders like asthma (29), patients with 
human immunodeficiency virus (HIV) infection 
(30), rheumatoid arthritis (31), Sjogren’s 
syndrome (32), type II diabetes (33), and sepsis 
(34). In a very recent study on first-episode 
schizophrenic patients, increased serum Trx 
was observed which was positively correlated 
with positive symptoms of schizophrenia (35). 
The elevated level of Trx1 has also been 
reported in patients with tumors, such as 
hepatocellular carcinoma (36) and pancreatic 
ductal carcinoma (23). The measurement of 
serum/plasma levels of Trx1 to evaluate the 
oxidative stress and prognosis in a number of 
diseases has been studied. For example, it is 
shown that the plasma level of Trx1 in HIV 
infection is negatively correlated with the levels 
of intracellular glutathione in lymphocytes and 
prognosis (37). The serum levels of Trx can Modifications and Applications of the Human Trx System 
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also be utilized to estimate the oxidative stress in 
chronic liver diseases such as nonalcoholic 
steatohepatitis (38) and hepatitis C virus 
infection (39), as well as cardiovascular 
disorders like acute ischemic heart disease (40) 
and chronic heart failure (41). When Trx1 is 
secreted, it is involved in a variety of physiologic 
and pathophysiologic functions. For example, 
secretory Trx1 acts as a co-cytokine and 
chemokine for immune cells, stimulating the 
growth of lymphocytes and in this way it is 
involved in immunomodulation (2, 42). Secreted 
Trx1 has also been suggested to be an autocrine 
growth factor for normal fibroblasts and several 
tumor cell lines (43). In addition, a truncated 
form of Trx (Trx80) which has the first 80 or 84 
N-terminal amino acids is identified which has 
been found to be secreted or located to the 
surface of monocytic cell lines (44). Trx80 is 
present in human plasma, enhancing 
eosinophilic cytotoxic activity compared to wild 
type Trx1 (44, 45). It also has the chemotactic 
activities for monocytes and polymorphonuclear 
neutrophiles as Trx1 possesses (46). Trx80 lacks 
the oxidoreductase activity of Trx1 even though 
it has the conserved active site, and it is not a 
substrate for TrxR. However, Trx80 can be 
reduced by Trx1 (47). 
Different factors are involved in the regulation 
of Trx activity, including its expression level, 
localization, protein-protein interaction, post-
translational modifications, and the inhibition by 
chemical substances.  It is also shown that Trx 
activity can be affected by a mechanical force. 
Wiita et al showed the inhibition of Trx activity 
and diminished antioxidant properties of the 
enzyme following the application of the 
increased mechanical forces (48). Regarding the 
expression of Trx1, there are different regulatory 
elements which affect the promoters of TXN1 
gene and induce the transcription. For instance, 
antioxidant responsive elements can induce the 
expression of Trx1 upon oxidative stress (49). 
The promoter region of TXN1 gene also 
contains other stress-responsive elements such as 
oxidative response (50) and heat shock 
responsive elements (51). The promoter region 
of the human TXN1 gene has regulatory binding 
motifs compatible with both constitutive or 
inducible expression (52). The expression of Trx 
is reported to increase because of different stress 
stimuli in cells such as O2 (53), H2O2 (54), 
photochemical oxidative stress, hypoxia (55), 
viral infections, lipopolysaccharide (56), X-
radiation and UV irradiation (57). The 
expression of Trx is also up-regulated by TNF-α, 
estrogen, and prostaglandin E1, and following 
the treatment with certain drugs such as 
adriamycin and a histone deacetylase inhinitor-
suberoylanilide hydroxamic acid (SAHA) (58), 
and during some diseases like heart failure, 
myocarditis and in atherosclerotic plaques (59). 
On the other hand, the expression of Trx is 
reported to be down-regulated by cathepsin D 
(60), SAHA (61) and hypertension (62). In fact 
under some certain conditions, the expression of 
Trx is either negatively or positively regulated, 
which can be explained by differences regarding 
cell types, cell conditions, or strength of 
stimulation. Post-translational modifications of 
Trx1 as well as the inhibitory effects of some 
chemicals will be discussed in details later. 
Thioredoxin reductases are the only enzymes 
which are able to reduce the active site of Trxs. 
Similar to Trxs, they are ubiquitously present in 
all living cells. Mammalian TrxRs are dimeric 
selenoproteins which have a conserved –Cys-
Val-Asn-Val-Gly-Cys- N-terminal active site 
(63). Another prominent feature of mammalian 
TrxRs is their C-terminal selenium-containing 
active site which is not present in TrxRs of lower 
organisms (64). The penultimate carboxyl-
terminal –Gly-Cys-Sec-Gly motif is essential for 
the redox activity of mammalian TrxRs (63), 
particularly regarding the Sec residue. Three 
isoenzymes for mammalian TrxRs have been 
introduced: TrxR1 which is mainly targeted to 
cytosol (65), TrxR2 which is in mitochondria 
(66), and the testis specific thioredoxin 
glutathione reductase (TGR) (67). The 
expression and intracellular concentration of 
TrxR1 can increase under prolonged oxidizing 
conditions, such as exposure of cells to H2O2 
(68). 
 
Modifications of Thioredoxin System 
The activity, structure, and/or localization of 
proteins can be modulated through the post-Seyed Isaac Hashemy  
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translational modifications of their amino acid 
residues. These modifications can be reversible 
or irreversible; however the former is the 
mechanism of choice for cellular regulation and 
signal transduction. There are a variety of 
proteins which are subjected to different kinds of 
post-translational modifications, and some can 
be regulated by more than one type of 
modifications. Human Trx1 is an example that 
can be modulated via different modifications, 
which are suggested to be involved in signaling 
pathways.  
Besides two Cys residues in the redox-
regulatory domain of Trx1 which are common 
in all kingdoms of life, mammalian cytosolic 
Trxs have additional structural cysteines which 
are first reported to be involved in protein 
aggregation and inactivation via their oxidation 
(69). Human Trx1 has three additional Cys 
residues at positions 62, 69 and 73 which have 
unknown biological functions (Fig. 1); 
however, it is suggested that they can be 
modified leading to the regulation of Trx1 
activity. Among these structural cysteine 
residues, Cys 73 is the closest one to the active 
site in the three-dimensional structure of Trx, 
protruding from the surface. 
Post-translational modifications of human 
Trx1 which are involved in the regulation of its 
activity can happen via modification of Cys 
residues including thiol oxidation, 
glutathionylation and S-nitrosylation or it may 
occur via modification of other amino acid 
residues such as nitration of Tyr 49. 
 
 
 
Figure 1. Human cytosolic Trx1 (PDB code: 1ERT) 
 
An intermolecular disulfide bond has been 
identified via Cys 73 residues of two Trx1 
molecules, suggested to be involved in 
homodimerization (70); though it is not 
essential for dimerization (71). 
Homodimerization of human Trx1 in solution 
occurs especially under strong oxidizing 
conditions or when it is stored at high 
concentrations. After homodimerization of 
Trx1 via a disulfide bond between two Cys 73 
residues, the active site is inaccessible to TrxR, 
and Trx activity is therefore inhibited (71, 72). 
The physiological importance of Trx1 
dimerization is not known. Interestingly, the 
homodimerization of Trx in the oxidizing 
extracellular environment limits the growth-
stimulating effects of this protein (73). Besides 
Cys 73, other structural cysteines are also 
involved in the formation of intermolecular 
disulfides since under strong oxidizing 
conditions, the formation of oligomers has also 
been reported (74). 
Under relatively mild oxidizing conditions, a 
second intramolecular disulfide bond may form 
between Cys 62 and Cys 69; which is not a 
substrate for TrxR and prohibits the reduction 
of active site disulfide by TrxR (75, 76). This 
inhibitory effect is probably mediated via 
attenuation the accessibility of TrxR to Trx1. 
The disulfide between Cys 62 and Cys 69 can 
be reduced by the active site of Trx1 (74). The 
formation of this intramolecular disulfide bond 
between two structural cysteines by diamide 
has been identified by mass scpectrometry, 
suggested to be involved in providing a redox 
mechanism for control of Trx1 function as well 
as providing more time for redox-dependent 
signaling processes (74, 76). 
S-glutathionylation, another kind of oxidative 
post-translational modification of proteins, is a 
reversible process that is suggested to be 
involved in the buffering of oxidative stress as 
well as the protection of proteins against 
irreversible oxidation and regulation of protein 
activity (77). S-glutathionylation of Trx1 is 
shown to occur at Cys 73 both in vitro as shown 
by mass spectrometry and in vivo after 
treatment of cells with diamide which is a 
strong oxidant generating oxidized glutathione 
(GSSG) (78). It happens during oxidative stress 
via formation of a mixed disulfide between the 
protein and reduced glutathione (GSH) (78). Modifications and Applications of the Human Trx System 
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Even though glutathionylation may occur under 
physiological conditions, Trx1 could only 
become glutathionylated under oxidative stress. 
The enzymatic oxidoreductase activity of Trx1 
was shown to be inhibited because of this 
modification; however, it is reversible via a 
process of auto-activation with sigmoidal 
kinetics. Glutathionylation of Trx has also been 
demonstrated in plants under conditions of 
oxidative stress (79). 
Trx1 can also be modified by reactive 
nitrogen species, leading to S-nitrosylation of 
the protein. For the first time, S-nitrosylation of 
Trx1 was reported by Haendeler et al in 2002. 
They reported that human cytosolic Trx is 
nitrosylated on Cys 69 under basal conditions, a 
modification which was necessary for its anti-
apoptotic function, scavenging reactive oxygen 
species as well as the redox regulatory activity 
via enzymatic activation (80). Thereafter, this 
modification has been extensively studied, 
leading to controversial results, showing the 
complexity of this area of research. In another 
study which was performed by Mitchell and 
Marletta, the S-nitrosylation of Trx1 was 
studied by mass spectrometry, immunological 
methods and site-directed mutagenesis. They 
reported that after treating His-tagged Trx1 
with 50 molar equivalents of nitrosoglutathione 
(GSNO), a nitrosylating agent, no modification 
of Cys 73 could be detected; Cys 69 was 
however fully nitrosylated and a disulfide 
bridge was formed between two cysteine 
residues in the active site (81). In this study, 
they also showed a transnitrosation process 
between caspase-3 and Trx1, which was proved 
later to be required for S-nitrosation of 
procaspase-3 and the inhibition of apoptosis in 
Jurkat cells (82). In addition to caspase-3, Trx 
is involved in the denitrosylation of several 
other proteins such as metallothionein, albumin 
and peroxiredoxin 1 (83, 85) as well as low 
molecular weight compounds containing 
nitrosothiols such as GSNO (86), S-nitroso-L-
cysteine (CysSNO), S-nitroso-L-homocysteine 
(HCysSNO), and S-nitroso-N-
acetylpenicillamine (SNAP) without any 
significant substrate selectivity (87). Sengupta 
et al showed that all HepG2 cell-derived S-
nitrosoproteins with a molecular mass of 23-30 
kDa are substrates for the Trx system. 
The first crystal structural study of 
nitrosylated Trx1 was done by Weichsel et al 
(88, 89). In this study, GSNO-treated human 
Trx1 did not exhibit any modification of Cys 
73. However, a disulfide bond was formed 
between Cys 32 and Cys 35, and Cys 62 and 
Cys 69 were nitrosylated. This nitrosylation 
was relatively stable, even in the presence of 1 
mM glutathione, and showed a pH-dependent 
pattern, i.e. at pH 7.0, 1 mol of S-NO/mol of 
Trx was found corresponding to the 
nitrosylation of Cys 62. While both Cys 62 and 
Cys 69 became nitrosylated at pH 9. At pH 5.6, 
no nitrosylation was detected (88).  
Regarding to this modification, I and my 
colleague showed that the fully reduced protein 
was nitrosylated by GSNO on both Cys 69 and 
Cys 73 in vitro; Cys 32 and Cys 35 which are in 
the active site of Trx1 were not nitrosylated by 
GSNO, but became oxidized to a disulfide 
bond. In addition, Pro 34 was involved in 
protection of the active site against S-
nitrosylation since the E. coli P34H Trx1 was 
sensitive to S-nitrosylation (74, 90). 
Interestingly, human cytosolic glutaredoxin 
(Grx1) which has a high homology to Trx1 
with three structural cysteines besides its two 
Cys residues in the active site does not show a 
same pattern of modification in response to 
nitrosylating agents such as GSNO (91). Under 
anaerobic conditions, all three structural 
cysteines of human Grx1 can be S-nitrosylated, 
suggesting that S-nitrosylation of human Trx1 
on only two of three structural cysteines should 
be a specific rather than a random modification. 
The physiological and pathophysiological 
significance of S-nitrosylation of mammalian 
Trxs as well as its kinetics remain to be fully 
explored.    Nitrosylation of Trx1 may 
provide a protective mechanism against 
irreversible oxidation of thiol groups or 
inactivation of the protein via disulfide 
formation between structural cysteines during 
oxidative and nitrosative stress. Nitrosylation of 
hTrx1 might be a protective effect against 
nitrative stress by removing NO, leading to the 
inhibition of ONOO
- formation. Seyed Isaac Hashemy  
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Moreover, Trx1 is reported to be affected by 
peroxynitrite via nitration of Tyr 49. 
Mammalian Trx1 has only one tyrosine which 
is located within a region that is essential for its 
folding. Nitration of this tyrosine residue leads 
to an irreversible inhibition of Trx1 redox 
regulatory activity through a conformational 
change. Nitrated Trx1 loses its antiapoptotic 
and cardioprotective effects as well (92), 
specially under hyperglycemic condition (93). 
The nitration of Trx1 also results in its 
dissociation from ASK-1, leading to ASK-1 
activation and apoptosis (92). The decrease of 
Trx activity in the aging heart was reported 
which was due to the post-translational nitrative 
modification and resulted in apoptotic 
cardiomyocyte death. According to this study, 
the expression of Trx is increased in the aging 
heart; and therefore, it does not contribute to the 
reduction of Trx activity (94). Peroxynitrite is 
also shown to inhibit the activity of TrxR in 
vivo via a reaction with the selenocysteine 
residue, a reaction which is irreversible (95). 
In a very recent study, glycation of Trx was 
reported for the first time as a novel post-
translational modification, inhibiting the 
oxidoreductase activity of Trx. But aminoacids 
which are involved in this modification are still 
unknown (96).  
The importance of other amino acids in the 
structure of Trxs and their effects on the 
activity and/or structure of these proteins has 
not been investigated as much as the Cys 
residues. However, there are several studies in 
this field which are mainly based on the 
mutagenesis of Trxs to investigate the effects 
on protein characteristics. For example, an 
extensive study has shown that two amino acids 
which are located in the active site between two 
redox active cysteines are crucial for the redox 
properties of Trx (97). 
 
Inhibitors of thioredoxin system and clinical 
applications 
Because of the numerous functions of the 
thioredoxin system, the inhibition of this 
oxidoreductase system which mainly happens 
via the targeting TrxR can result in major 
cellular consequences, e.g. less total antioxidant 
capacity, impairment of the whole reductive 
capacity of cells, increased levels of reactive 
oxygen species (ROS) and the subsequent 
oxidative stress, decreased GSH levels and 
increased GSSG and glutathionylated proteins, 
increased expression and secretion of Trx, 
increased expression of TrxR, and increased 
secretion of NF-κB- dependent proteins (98). 
Because of these effects which are potentially 
pro-oxidant in nature, inhibition of the Trx 
system results in cell death via necrosis or 
apoptosis if overexpression of Trx and other 
antioxidative enzymes can not recuperate the 
cell response (99). 
On the other hand, elevated levels of Trx 
and/or TrxR have been reported in many 
different human malignancies such as lung, 
hepatic, colorectal, pancreatic, thyroid, prostate 
and cervical cancer (100-102). The level of Trx 
and TrxR is positively correlated with 
aggressive tumor growth, poor prognosis and 
decreased patient survival (103-104). In a 
recent study, a positive correlation between Trx 
expression and the relapse of acute myeloid 
leukemia was reported (105). However, a 
relationship between Trx catalytic activity and 
tumor growth and stage is less clear. Yoo et al 
showed a direct role in carcinogenesis for 
TrxR1 in vivo, implicating that the enzyme is 
essential for the growth of a murine tumor 
(106). 
Moreover, several studies suggest that Trx 
may confer resistance to the cytotoxic effects of 
anti-cancer drugs. In one study with several 
human bladder and prostatic cancer cell lines 
resistant to cis-diamminedichloroplatinum(II) 
(cisplatin), all drug-resistant cell lines had much 
higher levels of thioredoxin than drug-sensitive 
cells. By introducing thioredoxin antisense 
expression plasmids into drug-resistant cell 
lines, increased sensitivity to cisplatin and also 
to other superoxide-generating agents, i.e., 
doxorubicin, mitomycin C, etoposide, and 
hydrogen peroxide, as well as to UV irradiation 
was observed (107). Tumor sensitivity to 
cisplatin is also negatively correlated with 
mRNA levels of Trx in hepatocellular carcinoma 
(108) and human cervical carcinoma cell lines 
(109). Resistance to adriamycin is also reported 
in various T-cell leukemia cell lines including 
adult T-cell leukemia (ATL) cell lines with high Modifications and Applications of the Human Trx System 
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expression of thioredoxin (110). In another 
study, the positive correlation between 
thioredoxin expression and resistance to 
docetaxel therapy in breast cancer patients was 
reported (111). This effect may be due to the role 
of Trx in cell survival and its anti-apoptotic 
functions, or may be derived from the 
scavenging of ROS which are increased during 
chemotherapy or radiation therapy, leading to 
the apoptosis. 
The Trx system provides tumor cells with a 
survival advantage through different 
mechanisms, such as its anti-apoptotic effects, 
role as a growth factor, stimulating angiogenesis, 
etc. Hence, this enzymatic system is an 
appealing target for anticancer therapy (112). 
Since thioredoxin reductase has a crucial role in 
the thioredoxin system and it has a highly 
reactive C-terminal active site which can be 
targeted by different electrophilic compounds, 
TrxR has been particularly considered as a target 
of anticancer agents (113).  Another feature of 
TrxR which makes it a good target for antitumor 
therapy is its inducible NADPH-oxidase activity 
which leads to formation of ROS. DNCB (1-
chloro-2,4-dinitrobenzene) is an electrophilic 
compound which irreversibly inhibits the 
activity of mammalian TrxRs with second order 
kinetics (114). This effect is due to the alkylation 
of both Cys and Sec residues in the C-terminal 
active site of NADPH-reduced TrxR (115). But 
upon alkylation, DNCB induces the NADPH 
oxidase activity of TrxR about 30-fold higher 
than the enzyme. This effect is dependent on the 
presence of oxygen, leading to an aerobic redox 
cycling and the formation of ROS (114). It has 
also been shown that certain anticancer drugs 
such as cisplatin as well as the chemopreventive 
agent curcumin form selenium-compromised 
thioredoxin reductase with an enhanced NADPH 
oxidase activity, leading to the production of 
more ROS and causing oxidative stress (109). In 
fact, these compounds switch TrxR from an 
antioxidant to a prooxidant. The irreversible 
inhibition of TrxR by curcumin is dose- and 
time-dependent and the curcumin-modified 
enzyme shows a strongly induced NADPH 
oxidase activity producing ROS (116). 
Motexafin gadolinium (MGd) is another 
cytotoxic drug which was initially introduced as 
a radiation sensitizer, selectively accumulates in 
tumor cells (117) and binds to TrxR, leading to 
the induction of its NADPH-oxidase activity as 
well as the inhibition of the protein-disulfide 
reductase activity of the enzyme (118). 
There are several anticancer compounds which 
are in clinical use and can inhibit TrxR, like 
retinoic acid (119), nitrosoureas such as 
carmustine (bis-chloroethyl-nitrosurea, BCNU) 
and fotemustine (120), platinum compounds 
such as cisplatin (109), and quinones (121).  
The inhibition of TrxR by BCNU and other 
nitrosourea drugs is irreversible and happens 
through carbamoylation of a cysteine in the 
catalytic site of reduced TrxR; hence oxidized 
enzyme is not a target for these compounds 
(122). Similar to nitrosourea drugs, cisplatin 
irreversibly inhibits the NADPH-reduced (but 
not oxidized) TrxR; however via covalent 
modification of the reduced selenocysteine 
residue. Recently, new platinum compounds 
have been synthesized which inhibit TrxR 
irreversibly with nanomolar concentrations 
directed to the C-terminal active site and 
micromolar affinities for the N-terminal active 
site (112). Phosphole complexes containing Au- 
and Pt-phospholes are new drug candidates 
which inhibit TrxR both in vitro and in cell 
culture (123). TrxR is also a target for arsenic 
trioxide which is an effective anticancer drug for 
acute promyelocytic leukemia with potential 
therapeutic applications in a wide range of solid 
tumors (124). 
The reducing activity of the Trx system can 
also be inhibited by an organotellurium analog 
of vitamin E which is able to inhibit the growth 
of tumor cells (125). Azelaic acid is another 
example of a suggested TrxR inhibitor with 
growth inhibitory effect on skin cells. Azelaic 
acid was proposed to competitively inhibit the 
electron transfer from the enzyme’s active site 
(126). 1, 2-[bis(1,2-benzisoselenazolone-3(2H)-
ketone)]ethane (BBSKE) is a novel 
organoselenium compound which was shown to 
be another thioredoxin reductase inhibitor with 
the inhibitory effect on the growth of a variety of 
human cancer cells (127). Wang et al showed 
the inhibition of TrxR in vivo as a molecular 
mechanism for ifosfamide, an oxazaphosphorine 
alkylating agent with a broad spectrum of Seyed Isaac Hashemy  
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antineoplastic activity in both adults and children 
(128). In this study, a transient inactivation of 
TrxR with an unknown mechanism was detected 
which was followed by a dramatic deceleration 
in tumor progression. This inhibitory effect was 
relatively specific to TrxR, since other 
antioxidants such as catalase, superoxide 
dismutase and glutathione S-transferase were not 
affected. The in vivo inhibition of TrxR has also 
been shown to be involved in antitumor effects 
of cyclophosphamide (129). 
Mammalian TrxRs can also be inhibited by a 
variety of low molecular weight electrophilic 
compounds such as thiol-alkylating compounds 
including 4- vinyl pyridine (115) and iodo-acetic 
acid (115), arsenicals (130), nitroaromatic 
compounds such as tetryl (131), quinone 
compounds (132), polyphenols (133), flavonoids 
(134), gold compounds (135), and 
dinitrohalobenzenes, e.g., DNCB (115). Gold is 
well-known for its affinity to thiols. Two gold-
containing antirheumatic drugs, auranofin and 
aurothioglucose, can inactivate the NADPH-
reduced form of TrxR at nanomolar 
concentrations via binding to the Sec residue 
(136). As mentioned above, DNCB is an 
irreversible inhibitor of human TrxR which 
modifies the selenocysteine residue and is 
uniquely capable of inducing the NADPH 
oxidase activity of TrxR simultaneously, leading 
to the formation of superoxide (114). The 
fluoride analoge to DNCB, 1-fluoro-2, 4-
dinitrobenzene (DNFB), is also an inhibitor of 
TrxR and induces the NADPH oxidase activity 
as well. Recently, Wataha et al showed the 
potent inhibition of TrxR1 activity by Hg (II) in 
both cell-free and intracellular assays using 
monocytes. This inhibition was dose-dependent 
and assumed to be mediated via thiol or selenol 
dependent mechanism. This mercurial 
compound is also shown to result in a transient 
decrease in Trx1 level which is suggested to 
happen because of Trx1 secretion (137). In 2008, 
I and my colleague analyzed the effects of 
mercuric chloride (HgCl2) and 
monomethylmercury (MeHg) on the Trx system 
both  in vitro and in vivo, showing that the 
inhibition of recombinant rat TrxR as well as the 
binding between fully reduced human Trx1 and 
mercury led to its oxidation and loss of the 
activity (138). Later, the inhibitory effect of 
methylmercury on mice thioredoxin reductase 
was also shown (139). The inhibitory effect of 
mercury on TrxR activity is reversible by 
selenite (140). 
Since the Trx system has crucial roles in cell 
survival, the inhibition of this system leads to 
different side effects. In order to partially 
overcome this problem, the inhibition of TrxR 
can be directed specifically to one of different 
isoenzymes. For example, mitochondrial TrxR2 
can be selectively inhibited by organogold(III) 
complexes, leading to Ca
2+-dependent 
mitochondrial membrane permeability and 
cytochrome C release (141). 
On the other hand, several compounds have 
been reported to affect the Trx system via the 
modification of Trx. PX-12 is such a drug, a 
substituted 2-imidazolyl disulfide which is in 
phase I clinical trial in patients with advanced 
metastatic cancer. PX-12 affects the activity of 
Trx via thioalkylation of Cys 73, and the effect is 
irreversible (142). Pleurotin is another inhibitor 
of Trx which decreases angiogenesis in cancer 
cells via the inhibition of hypoxia-induced 
factor-1α (HIF-1α) and vascular endothelial 
growth factor (VEGF) formation (142). 
The anti-oxidative and anti-apoptotic effects of 
Trx have been reasons for some investigators to 
study the clinical application of Trx as a drug. 
This approach seems especially appealing 
because of the small size and stable structure of 
Trx, which can function both intracellularly and 
extracellularly. This goal can be achieved by 
means of exogenous Trx which can enter into 
cells or via the induction of Trx1 expression. 
The administration of recombinant human Trx 
and its therapeutic advantages have been studied 
for acute lung injury (143), and cerebral 
ischemia (144). The protective effect of 
exogenous Trx in cardiovascular diseases such 
as autoimmune myocarditis (145), reperfusion-
induced arrhythmias (146), myocardial apoptosis 
and infarct size (147), and age-induced cardiac 
hypertrophy and fibrosis (148) has also been 
shown. The application of Trx1 gene therapy for 
the regulation of angiogenic signaling and 
ventricular remodeling in infarcted myocardium 
of diabetic rats was also recently reported (149). 
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